These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 22355307)

  • 21. Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis.
    Lathouwers E; De Meyer S; Dierynck I; Van de Casteele T; Lavreys L; de Béthune MP; Picchio G
    Antivir Ther; 2011; 16(1):99-108. PubMed ID: 21311113
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes.
    Wilkin TJ; McKinnon JE; DiRienzo AG; Mollan K; Fletcher CV; Margolis DM; Bastow B; Thal G; Woodward W; Godfrey C; Wiegand A; Maldarelli F; Palmer S; Coffin JM; Mellors JW; Swindells S
    J Infect Dis; 2009 Mar; 199(6):866-71. PubMed ID: 19191590
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of lopinavir-ritonavir exposure in HIV-1 infected children and adolescents in Madrid, Spain during 2000-2014.
    Rojas Sánchez P; Prieto L; Jiménez De Ory S; Fernández Cooke E; Navarro ML; Ramos JT; Holguín Á;
    PLoS One; 2017; 12(3):e0173168. PubMed ID: 28350802
    [TBL] [Abstract][Full Text] [Related]  

  • 24. First-line antiretroviral therapy with nevirapine versus lopinavir-ritonavir based regimens in a resource-limited setting.
    Clumeck N; Mwamba C; Kabeya K; Matanda S; Vaira D; Necsoi C; Kadiebwe D; Delforge M; Kasamba E; Milolo C; Ilunga J; Kapend L
    AIDS; 2014 May; 28(8):1143-53. PubMed ID: 25028911
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial.
    Hill A; Marcelin AG; Calvez V
    HIV Med; 2009 Nov; 10(10):620-6. PubMed ID: 19601995
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lopinavir/ritonavir resistance in patients infected with HIV-1: two divergent resistance pathways?
    Champenois K; Baras A; Choisy P; Ajana F; Melliez H; Bocket L; Yazdanpanah Y
    J Med Virol; 2011 Oct; 83(10):1677-81. PubMed ID: 21755502
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.
    Daar ES; Tierney C; Fischl MA; Sax PE; Mollan K; Budhathoki C; Godfrey C; Jahed NC; Myers L; Katzenstein D; Farajallah A; Rooney JF; Pappa KA; Woodward WC; Patterson K; Bolivar H; Benson CA; Collier AC;
    Ann Intern Med; 2011 Apr; 154(7):445-56. PubMed ID: 21320923
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naïve human immunodeficiency virus-infected patients in the United States.
    Broder MS; Chang EY; Bentley TG; Juday T; Uy J
    J Med Econ; 2011; 14(2):167-78. PubMed ID: 21288058
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients.
    Santoro MM; Bertoli A; Lorenzini P; Ceccherini-Silberstein F; Gianotti N; Mussini C; Torti C; Di Perri G; Barbarini G; Bini T; Melzi S; Caramello P; Maserati R; Narciso P; Micheli V; Antinori A; Perno CF;
    Infection; 2009 Jun; 37(3):233-43. PubMed ID: 19169632
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Deep sequencing reveals minor protease resistance mutations in patients failing a protease inhibitor regimen.
    Fisher R; van Zyl GU; Travers SA; Kosakovsky Pond SL; Engelbrech S; Murrell B; Scheffler K; Smith D
    J Virol; 2012 Jun; 86(11):6231-7. PubMed ID: 22457522
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients.
    Masquelier B; Breilh D; Neau D; Lawson-Ayayi S; Lavignolle V; Ragnaud JM; Dupon M; Morlat P; Dabis F; Fleury H;
    Antimicrob Agents Chemother; 2002 Sep; 46(9):2926-32. PubMed ID: 12183249
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunological and Virological Outcomes of Patients Switched from LPV/r to ATV/r-Containing Second- Line Regimens.
    Akanmu AS; Adeyemo T; Lesi F; Bello FO; Okwuegbuna K; Oloko K; Awolola A; Ogunsola FT; Okonkwo P; Kanki PJ
    Curr HIV Res; 2015; 13(3):176-83. PubMed ID: 25986368
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice.
    Prosperi MC; Zazzi M; Punzi G; Monno L; Colao G; Corsi P; Di Giambenedetto S; Meini G; Ghisetti V; Bonora S; Pecorari M; Gismondo MR; Bagnarelli P; Carli T; De Luca A;
    J Med Virol; 2010 Dec; 82(12):1996-2003. PubMed ID: 20981785
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical utility of atazanavir].
    Ribera Pascuet E; Curran A
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():55-67. PubMed ID: 20116619
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial.
    Piketty C; Gérard L; Chazallon C; Marcelin AG; Clavel F; Taburet AM; Calvez V; Madelaine-Chambrin I; Molina JM; Aboulker JP; Girard PM;
    Antivir Ther; 2006; 11(2):213-21. PubMed ID: 16640102
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatment-experienced patients.
    Naeger LK; Struble KA
    AIDS; 2006 Apr; 20(6):847-53. PubMed ID: 16549968
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Virological response and resistance profiles after 24 months of first-line antiretroviral treatment in adults living in Bangui, Central African Republic.
    Péré H; Charpentier C; Mbelesso P; Dandy M; Matta M; Moussa S; De Dieu Longo J; Grésenguet G; Abraham B; Bélec L
    AIDS Res Hum Retroviruses; 2012 Apr; 28(4):315-23. PubMed ID: 21942692
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naïve HIV-infected patients: SPARTAN study results.
    Kozal MJ; Lupo S; DeJesus E; Molina JM; McDonald C; Raffi F; Benetucci J; Mancini M; Yang R; Wirtz V; Percival L; Zhang J; Zhu L; Arikan D; Farajallah A; Nguyen BY; Leavitt R; McGrath D; Lataillade M; The Spartan Study Team
    HIV Clin Trials; 2012; 13(3):119-30. PubMed ID: 22592092
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients.
    De Meyer S; Lathouwers E; Dierynck I; De Paepe E; Van Baelen B; Vangeneugden T; Spinosa-Guzman S; Lefebvre E; Picchio G; de Béthune MP
    AIDS; 2009 Sep; 23(14):1829-40. PubMed ID: 19474650
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiviral activity and clinical efficacy of atazanavir in HIV-1-infected patients: a review.
    Gianotti N; Soria A; Lazzarin A
    New Microbiol; 2007 Apr; 30(2):79-88. PubMed ID: 17619250
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.